NCT01127308View on ClinicalTrials.gov

A Radiolabeled Mass Balance Study of [14C]-Ertugliflozin (PF04971729, MK-8835) In Healthy Male Participants (MK-8835-038)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Ertugliflozin

Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of \[14C\]ertugliflozin

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY